NVS - Novartis AG
| Previous Close | 79.74 |
| Open | 77.54 |
| Bid | 78.95 x 800 |
| Ask | 80.00 x 1000 |
| Day's Range | 77.16 - 81.04 |
| 52 Week Range | 69.18 - 99.84 |
| Volume | 2,654,041 |
| Avg. Volume | 2,743,967 |
| Market Cap | 176.716B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 15.67 |
| EPS (TTM) | 5.06 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.09 (3.87%) |
| Ex-Dividend Date | Mar 02, 2020 |
| 1y Target Est | 102.67 |
- Reuters
Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitung
Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit's malaria, lupus and arthritis drug hydroxychloroquine is the company's biggest hope against the coronavirus, Swiss newspaper SonntagsZeitung reported on Sunday. Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which U.S. President Donald Trump also has been promoting, can be approved for use against the coronavirus. Other companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing its experimental drug remdesivir against coronavirus.
- GuruFocus.com
Covid-19 Could Benefit Generic Drug Companies
Pricing is increasing for makers of copycat medicines Continue reading...
- Benzinga
Novartis CEO Talks Coronavirus Vaccine Progress, Timeline
The world is progressing towards a vaccine for the coronavirus with multiple large-scale and properly controlled studies exploring the efficacy of hydroxychloroquine, Novartis AG (NYSE: NVS) CEO Vas Narasimhan said on CNBC.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Narasimhan said ongoing studies consist of giving doses of hydroxychloroquine to hospitalized patients and other people who may have been exposed to the coronavirus. The trials are moving at a rapid pace, including a Novartis-sponsored study and other investigative trials and "a lot more data" should come out within the following month.Narasimhan said it's already known from pre-clinical studies involving animals so far have shown that hydroxychloroquine is "quite active against the coronavirus." Meanwhile, the drug is currently being used across the world as doctors are vying to give patients "any option they can."Why It's ImportantIt's too early to declare hydroxychloroquine is a proven therapy for coronavirus and this conclusion can't be reached until the properly controlled and randomized studies are completed, he said.Novartis and its rivals are also actively testing existing medicines to see if it can "kill the virus" in people or help boost the immune system that the virus targets, Narasimhan said.What's Next Novartis along with multiple other companies announced Thursday a new partnership with the Gates Foundation in which Narasimhan will serve as co-chair. He said the objective is to find novel therapies to treat the infection. But any working vaccine is likely 18 to 24 months away and this is the "definitive way" to deal with the pandemic.The one important aspect of a vaccine to keep in mind is that it is given to healthy people and needs to be proven before to be both safe and effective, he said. As such, the more pressing near-term priority is to take existing drugs to treat the virus or treat the auto-immune reaction. A "realistic" timeline for this achievement is over the next 12 months.See more from Benzinga * General Mills CEO: Everyone Is 'Doing The Job They Need To Do' * Mondelez CEO Talks Global Food Demand And More * GrubHub CEO: Independent Restaurants Are 'Really Hurting'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- TheStreet.com
Novartis CEO Cautions on Efficacy of Trump-Touted Covid-19 Treatment
Novartis CEO says it's 'too soon' to be sure whether two of the company's anti-malaria drugs could prove to be an effective treatment for the novel coronavirus.
- Investor's Business Daily
How Bristol Myers' New MS Drug Has A Leg-Up On A Rival From Novartis
Shares of Bristol Myers Squibb stock popped Thursday after the pharmaceutical company grabbed U.S. approval for a key multiple sclerosis treatment, ozanimod. It's now known as Zeposia.
- The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan MergerBenzinga
- Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active DiseaseBusiness Wire
- Business Wire
ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
- MoneyShow
Golds, Resources and Investing in the "New Normal"
The moves in the financial markets have been gut-wrenching. However, I'm an optimist and I do believe in the ascent of man. Humanity will prevail, asserts Omar Ayales, editor of Gold Charts R Us.
- Barrons.com
Companies Plan to Boost Production of Controversial Malaria Drug as Demand Jumps
Demand for hydroxychloroquine, the malaria drug that President Trump has touted as a treatment for Covid-19 despite limited evidence, has already begun to increase, according to a note from SVB Leerink analyst Ami Fadia.
- Benzinga
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) (follow-on rally from Friday's news of FDA authorization of emergency use of inhaled nitric oxide delivery system to treat COVID-19)Down In The Dumps (Biotech stocks that hit 52-week lows March 23.) * Abbott Laboratories (NYSE: ABT) * AbbVie Inc (NYSE: ABBV) * ABIOMED, Inc. (NASDAQ: ABMD) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Acer Therapeutics Inc (NASDAQ: ACER) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * Anixa Biosciences Inc (NASDAQ: ANIX) * Antares Pharma Inc (NASDAQ: ATRS) * Apyx Medical Corp (NASDAQ: APYX) * Avanos Medical Inc (NYSE: AVNS) * BIO-TECHNE Corp (NASDAQ: TECH) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) * DelMar Pharmaceuticals Inc (NASDAQ: DMPI) * Edwards Lifesciences Corp (NYSE: EW) * Erytech Pharma SA (NASDAQ: ERYP) * Exicure Inc (NASDAQ: XCUR) * GlaxoSmithKline plc (NYSE: GSK) * Imv Inc (NASDAQ: IMV) * Incyte Corporation (NASDAQ: INCY) * Inspire Medical Systems Inc (NYSE: INSP) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Ionis Pharmaceuticals Inc (NASDAQ: IONS) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Johnson & Johnson (NYSE: JNJ) * Kindred Biosciences Inc (NASDAQ: KIN) * LeMaitre Vascular Inc (NASDAQ: LMAT) * Lumos Pharma Inc (NASDAQ: LUMO) * Magenta Therapeutics Inc (NASDAQ: MGTA) * Merck & Co., Inc. (NYSE: MRK) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Mesoblast limited (NASDAQ: MESO) * Misonix Inc (NASDAQ: MSON) * NanoVibronix Inc (NASDAQ: NAOV) * Neovasc Inc (NASDAQ: NVCN) * OptiNose Inc (NASDAQ: OPTN) * Outlook Therapeutics Inc (NASDAQ: OTLK) * Pacira Biosciences Inc (NASDAQ: PCRX) * PDS Biotechnology Corp (NASDAQ: PDSB) * Penumbra Inc (NYSE: PEN) * PLx Pharma Inc (NASDAQ: PLXP) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precipio Inc (NASDAQ: PRPO) * Psychemedics Corp. (NASDAQ: PMD) * Quest Diagnostics Inc (NYSE: DGX) * Salarius Pharmaceuticals Inc (NASDAQ: SLRX) * Sanofi SA (NASDAQ: SNY) * Sellas Life Sciences Group Inc (NASDAQ: SLS) * TherapeuticsMD Inc (NASDAQ: TXMD) * Urogen Pharma Ltd (NASDAQ: URGN) * Zoetis Inc (NYSE: ZTS)Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See also: The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus Stocks In Focus Milestone Pharma's Abnormal Heart Rhythm Drug Fails To Meet Primary Endpoint In Late-Stage Study Milestone Pharmaceuticals Inc (NASDAQ: MIST) said the Phase 3 study dubbed NODE-301 that evaluated its investigational therapy etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia, or SVT, did not achieve its primary endpoint of time to conversion of SVT to sinus rhythm compared to placebo over the five-hour period following the study drug administration.Top-line results from the study that evaluated a 70mg dose in 431 patients enrolled across 65 sites in the U.S. and Canada showed the median time to conversion of the treatment arm was 25 minutes compared to 45 minutes for the control arm, which was not statistically significant."We will continue to execute as prudently possible on the ongoing NODE studies, including NODE-301B, and look forward to reviewing these data with regulators," said Joseph Oliveto, CEO of Milestone.The stock was falling 73.21% to $3.75 in Tuesday's premarket session. Novartis' Zolgensma Found Efficacious In Long-Term Follow-Up Study Novartis AG (NYSE: NVS) released new data from the START long-term follow-up study of its SMA gene therapy Zolgensma, which showed a rapid, significant, clinically meaningful benefit, including prolonged event-free survival, motor milestone achievement and durability up to five years post-dosing.In the STRIVE-US study, about 91% of the patients met the co-primary efficacy endpoint of event-free survival at 14 months and more than half of patients sitting for more than 30 seconds at 18 months of age.The company also said interim data from the ongoing SPR1NT study continued to show patients achieving age-appropriate motor milestones when treated with Zolgensma presymptomatically.Separately, the company's Sandoz generic unit said it has acquired the distribution rights in the U.S. for daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG in a bid to grow its injectables portfolio and overall offerings in the hospital setting.The stock was trading 4.87% higher at $74.11 in Tuesday's premarket session. Novavax's Flu Vaccine Candidate Achieves Primary, Key Secondary End Points In Pivotal Late-Stage Study Announcing top-line results of a pivotal Phase 3 study of NanoFlu, Novavax, Inc. (NASDAQ: NVAX) said its recombinant quadrivalent seasonal influenza vaccine candidate with its Matrix-M adjuvant achieved all primary endpoints as well statistical significance in key secondary end points. The study evaluated the immunogenicity and safety of NanoFlu compared to Sanofi's Fluzone Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.The company said it expects to submit a BLA under the FDA's accelerated approval pathway.The stock was surging 46.56% to $15.77 in premarket trading Tuesday.CytomX Announces Cancer Drug Collaboration With Astellas For Up To $1.6B CytomX Therapeutics Inc (NASDAQ: CTMX) and ASTELLAS PHARMA/ADR (OTC: ALPMY) announced a strategic collaboration agreement for the research and development of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for treating cancer using CytomX's Probody therapeutic technology platform as well as its proprietary bispecific formats and CD3 models.Under the agreement, CytomX will be responsible for research and discovery activities up to clinical candidate selection, while Astellas will finance the activities. Astellas will then assume the responsibility for preclinical and clinical development as well as financing.View more earnings on IBBCytomX will receive an upfront cash payment of $80 million, and is also eligible to receive future preclinical, clinical and commercial milestones of over $1.6 billion. CytomX is also eligible to receive tiered royalties on global net sales in the high-single digits to mid-teens range.Separately, CytomX announced the appointment of Carlos Campoy as its SVP and CFO.GenMark Obtains BARDA Grant For COVID-19 Diagnostic Test Development, Approval GenMark Diagnostics, Inc (NASDAQ: GNMK) said the Biomedical Advanced Research and Development Authority has awarded it a grant up to $749,000 to fund the development and acquisition of FDA Emergency Use Authorization for its diagnostic panel that incorporates the new SARS-CoV-2 viral target into its existing ePlex Respiratory Pathogen panel.The company said it expects the funding support to enable it to complete the development work necessary to request an EUA from the FDA for the ePlex RP2 Panel.The stock was adding 5.42% to $4.47 in premarket trading Tuesday.Qiagen Begins US Shipments Of Coronavirus Panel Test Qiagen NV(NYSE: QGEN) said it has begun shipments of its new QIAstat-Dx Respiratory SARS-CoV0-2 Panel Test to the U.S. to help diagnose infected persons. The shipments were in accordance with the new FDA policy announced March 16. The company said it will submit the EUA application to the FDA this week.Qiagen shares were trading 3.31% higher to $39.36 in Tuesday's premarket session. Cumberland Securing Supply Of Antibiotic For COVID-19-Related Pneumonia Cumberland Pharma announced it is taking appropriate action to secure its supply chain for its potent antibiotic Vibativ injection to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of the COVID-19 disease.The company said it will also make available special financing arrangements for hospitals and clinics to ensure supply. It is also sponsoring a national program with infectious disease experts to provide information on the management of complicated respiratory infections resulting from the novel coronavirus.In premarket trading Tuesday, the stock was rising 11.85% to $4.06. Applied DNA Files Patent Application For Coronavirus Diagnostic Assay Applied DNA Sciences Inc (NASDAQ: APDN) announced the filing of a provisional patent application with the U.S. Patent and Trademark Office for its diagnostic assay under development for SARS-CoV-2, the virus that causes COVID-19. In premarket trading Tuesday, Applied DNA shares were rallying 12.56% to $4.48.PDS Biotech CFO Quits PDS Biotech said its CFO Andrew Saik has resigned from his position and as a director effective immediately to pursue other opportunities. The company said it has initiated a search to identify a successor.The stock was moving up 5.26% to 30 cents in premarket trading Tuesday.Urovant Appoints Jim Robinson As CEO Urovant Sciences Ltd (NASDAQ: UROV) said it has appointed Jim Robinson to the position of president and CEO, succeeding its founder Keith Katkin. Katkin, according to the company, will transition to an advisory role.Offerings Hoth Therapeutics Inc (NASDAQ: HOTH) said it intends to offer shares of its common stock in a "best efforts" underwritten public offering.The stock was slipping 16.84% to $3.11 in premarket trading Tuesday.Baudax Bio Inc (NASDAQ: BXRX) said it has commenced an underwritten public offering of its common stock, Series A warrants and Series B warrants. All the securities offered are being sold by Baudax.The company said it intends to use the net proceeds for the commercial launch of Anjeso, pipeline development activities and general corporate purposes.The stock was slumping 26.77% to $3.20 in premarket trading Tuesday.On The Radar Earnings * Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close) * OpGen Inc (NASDAQ: OPGN) (after the close) * Onconova Therapeutics Inc (NASDAQ: ONTX) (after the close) * Sol Gel Technologies Ltd (NASDAQ: SLGL)Related Link: Hoth Therapeutics Shares Jump On COVID-19 Vaccine Development Plans See more from Benzinga * The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company * 12 Key Medical Meetings Canceled Or Postponed In The Face Of A Pandemic(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Investor's Business Daily
The Biggest Biotech Is Expected To Grow — But Is It Enough To Be A Buy?
Amgen stock is facing concerns that biosimilars could chip away at some of its biggest moneymakers. Is it time to buy shares of the biotech company?
- Zacks
Novartis to Donate Generic Hydroxychloroquine for Coronavirus
Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.
- Zacks
J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.
- Benzinga
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) * Imara Inc (NASDAQ: IMRA)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) * 89bio Inc (NASDAQ: ETNB) * AC Immune SA (NASDAQ: ACIU) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adamis Pharmaceuticals Corp (NASDAQ: ADM) * Adial Pharmaceuticals Inc (NASDAQ: ADIL) * ADMA Biologics Inc (NASDAQ: ADMA) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Agenus Inc (NASDAQ: AGEN) * Agios Pharmaceuticals Inc (NASDAQ: AGIO) * Aikido Pharma Inc (NASDAQ: AIKI) * Akorn, Inc. (NASDAQ: AKRX) * Alkermes Plc (NASDAQ: ALKS) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) * Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) * AngioDynamics, Inc. (NASDAQ: ANGO) * Anika Therapeutics Inc (NASDAQ: ANIK) * Anixa Biosciences Inc (NASDAQ: ANIX) * Antares Pharma Inc (NASDAQ: ATRS) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Aptinyx Inc (NASDAQ: APTX) * Arca Biopharma Inc (NASDAQ: ABIO) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Aridis Pharmaceuticals Inc (NASDAQ: ARDS) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Athenex Inc (NASDAQ: ATNX) * Avanos Medical Inc (NYSE: AVNS) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) * BIO-TECHNE Corp (NASDAQ: TECH) * BioCardia Inc (NASDAQ: BCDA) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * BIOFRONTERA AG/ADR (NASDAQ: BFRA) * BIOLASE Inc (NASDAQ: BIOL) * BIOLINERX LTD/S ADR (NASDAQ: BLRX) * BioNano Genomics Inc (NASDAQ: BNGO) * BioSig Technologies Inc (NASDAQ: BSGM) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) * BioTelemetry Inc (NASDAQ: BEAT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Boston Scientific Corporation (NYSE: BSX) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Cabaletta Bio Inc (NASDAQ: CABA) * Caladrius Biosciences Inc (NASDAQ: CLBS) * Cara Therapeutics Inc (NASDAQ: CARA) * CareDx Inc (NASDAQ: CDNA) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) * Catalent Inc (NYSE: CTLT) * Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Cellectis SA (NASDAQ: CLLS) * CELYAD SA/ADR (NASDAQ: CYAD) * Chiasma Inc (NASDAQ: CHMA) * Chimerix Inc (NASDAQ: CMRX) * Coherus Biosciences Inc (NASDAQ: CHRS) * DelMar Pharmaceuticals Inc (NASDAQ: DMPI) * Dyadic International, Inc. (NASDAQ: DYAI) * Edesa Biotech Inc (NASDAQ: EDSA) * Elanco Animal Health Inc (NYSE: ELAN) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Enzo Biochem, Inc. (NYSE: ENZ) * Erytech Pharma SA (NASDAQ: ERYP) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evogene Ltd (NASDAQ: EVGN) * EXACT Sciences Corporation (NASDAQ: EXAS) * Exicure Inc (NASDAQ: XCUR) * Eyenovia Inc (NASDAQ: EYEN) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * FibroGen Inc (NASDAQ: FGEN) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Flexion Therapeutics Inc (NASDAQ: FLXN) * Galera Therapeutics Inc (NASDAQ: GRTX) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) * Genocea Biosciences Inc (NASDAQ: GNCA) * Glaukos Corp (NYSE: GKOS) * Global Cord Blood Corp (NYSE: CO) * Global Blood Therapeutics Inc (NASDAQ: GBT) * GlycoMimetics Inc (NASDAQ: GLYC) * Gossamer Bio Inc (NASDAQ: GOSS) * Gritstone Oncology Inc (NASDAQ: GRTS) * Haemonetics Corporation (NYSE: HAE) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Harvard Bioscience, Inc. (NASDAQ: HBIO) * Helius Medical Technologies Inc (NASDAQ: HSDT) * Hepion Pharmaceuticals Inc (NASDAQ: HEPA) * Hologic, Inc. (NASDAQ: HOLX) * Illumina, Inc. (NASDAQ: ILMN) * Immunovant Inc (NASDAQ: IMVT) * Incyte Corporation (NASDAQ: INCY) * Innovate Biopharmaceuticals Inc (NASDAQ: INNT) * Innoviva Inc (NASDAQ: INVA) * Insmed Incorporated (NASDAQ: INSM) * Inspire Medical Systems Inc (NYSE: INSP) * Intec Pharma Ltd (NASDAQ: NTEC) * Integra Lifesciences Holdings Corp (NASDAQ: IART * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Iterum Therapeutics PLC (NASDAQ: ITRM) * Jaguar Health Inc (NASDAQ: JAGX) * Kalvista Pharmaceuticals Inc (NASDAQ: KALV) * KemPharm Inc (NASDAQ: KMPH) * Kezar Life Sciences Inc (NASDAQ: KZR) * Kindred Biosciences Inc (NASDAQ: KIN) * Kura Oncology Inc (NASDAQ: KURA) * Laboratory Corp. of America Holdings (NYSE: LH) * Lantheus Holdings Inc (NASDAQ: LNTH) * Liminal BioSciences Inc (NASDAQ: LMNL) * Lipocine Inc (NASDAQ: LPCN) * MacroGenics Inc (NASDAQ: MGNX) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Mallinckrodt PLC (NYSE: MNK) * Medigus Ltd. (NASDAQ: MDGS) * Medtronic PLC (NYSE: MDT) * MEI Pharma Inc (NASDAQ: MEIP) * MeiraGTx Holdings PLC (NASDAQ: MGTX) * Menlo Therapeutics Inc (NASDAQ: MNLO) * MEREO BIOPHARMA/ADR (NASDAQ: MREO) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Merus NV (NASDAQ: MRUS) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) * Miragen Therapeutics Inc (NASDAQ: MGEN) * Morphosys Ag (NASDAQ: MOR) * MYOS Corporation common stock (NASDAQ: MYOS) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Natera Inc (NASDAQ: NTRA) * Natus Medical Inc (NASDAQ: NTUS) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * Neuronetics Inc (NASDAQ: STIM) * NewLink Genetics Corp (NASDAQ: NLNK) * Novus Therapeutics Inc (NASDAQ: NVUS) * NuVasive, Inc. (NASDAQ: NUVA) * Obalon Therapeutics Inc (NASDAQ: OBLN) * OptiNose Inc (NASDAQ: OPTN) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organovo Holdings Inc (NASDAQ: ONVO) * Orthofix Medical Inc (NASDAQ: OFIX) * Otonomy Inc (NASDAQ: OTIC) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Outlook Therapeutics Inc (NASDAQ: OTLK) * Pacific Biosciences of California (NASDAQ: PACB) * Pacira Biosciences Inc (NASDAQ: PCRX) * Passage Bio Inc (NASDAQ: PASG) * PDS Biotechnology Corp (NASDAQ: PDSB) * PLx Pharma Inc (NASDAQ: PLXP) * Precipio Inc (NASDAQ: PRPO) * Predictive Oncology Inc (NASDAQ: POAI) * Psychemedics Corp. (NASDAQ: PMD) * Quest Diagnostics Inc (NYSE: DGX) * Rapt Therapeutics Inc (NASDAQ: RAPT) * REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) * Regenxbio Inc (NASDAQ: RGNX) * resTORbio, Inc. (NASDAQ: TORC) * Retrophin Inc (NASDAQ: RTRX) * Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Salarius Pharmaceuticals Inc NASDAQ: SLRX * SCYNEXIS Inc (NASDAQ: SCYX) * Seneca Biopharma Inc (NASDAQ: SNCA) * Shockwave Medical Inc (NASDAQ: SWAV) * SI-Bone Inc (NASDAQ: SIBN) * Sierra Oncology Inc (NASDAQ: SRRA) * Silk Road Medical Inc (NASDAQ: SILK) * Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * SurModics, Inc. (NASDAQ: SRDX) * Takeda Pharmaceutical Co Ltd (NYSE: TAK) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * TELA Bio Inc (NASDAQ: TELA) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Therapix Biosciences Ltd - ADR (NASDAQ: TRPX) * Theratechnologies Inc (NASDAQ: THTX) * Titan Medical Inc. (NASDAQ: TMDI) * Trevena Inc (NASDAQ: TRVN) * Trevi Therapeutics Inc (NASDAQ: TRVI) * Tricida Inc (NASDAQ: TCDA) * Trinity Biotech plc (NASDAQ: TRIB) * TrovaGene Inc (NASDAQ: TROV) * Twist Bioscience Corp (NASDAQ: TWST) * Urogen Pharma Ltd (NASDAQ: URGN) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Vascular Biogenics Ltd (NASDAQ: VBLT) * Veracyte Inc (NASDAQ: VCYT) * Vericel Corp (NASDAQ: VCEL) * VERONA PHARMA P/S ADR (NASDAQ: VRNA) * Viveve Medical Inc (NASDAQ: VIVE) * VIVUS, Inc. (NASDAQ: VVUS) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Xenetic Biosciences Inc (NASDAQ: XBIO) * Xenon Pharmaceuticals Inc (NASDAQ: XENE) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zimmer Biomet Holdings Inc (NYSE: ZBH) * Zoetis Inc (NYSE: ZTS) * Zogenix, Inc. (NASDAQ: ZGNX)See Also: 8 Biotechs With Coronavirus Vaccines In DevelopmentStocks In Focus Moleculin To Test Candidates For Coronavirus Canada's WPD Pharma said its licensing partner Moleculin Biotech Inc (NASDAQ: MBRX) has entered into an agreement with a leading government funded research facility in the U.S. to conduct research on its patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus.In pre-market trading Thursday, Moleculin stock was rallying 134.49% to $1.10.Roche's Genentech To Evaluate Drug For COVID-19 Pneumonia Roche Holdings AG Basel ADR (OTC: RHHBY)'s Genentech unit said it is working with the BARDA to evaluate the safety and efficacy of Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.The company said the global study is expected to begin enrolling as soon as possible in early April with 330 patients.Novartis's Zolgensma Gets Japanese Regulatory Approval Novartis AG (NYSE: NVS) said the Japanese Ministry of Health, Labor and Welfare approved its gene therapy Zolgensma for treating spinal muscular atrophy in patients aged under two.Separately, the company said it is voluntarily recalling 100mg sandimmune and neural prescription drug blister packages due to the failure to meet child-resistant packaging requirement. If it is consumed by children, it exposes them to toxicity risk, the company said.Separately, the company announced publication in the New England Journal of Medicine results of three pivotal Phase III clinical trials for inclisiran, a siRNA investigational agent for hyperlipidemia in adults, which showed achievement of primary endpoints and safety.J&J Submits NDA For Multiple Sclerosis Drug Johnson & Johnson (NYSE: JNJ)'s Janssen unit announced the submission of an NDA, seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis.Bio-Rad's Real-Time qPCR Products Used by Labs For COVID-10 Screening Bio-Rad Laboratories, Inc. (NYSE: BIO) said its Real-Time qPCR products are being used by testing laboratories globally to screen for COVID-19.Dyadic's Platform to be Used By Israeli Research Institution to Develop COVID-19 Treatment Participating in the 32nd Annual ROTH Conference, which was held virtually, Dyadic said the Israeli Institute For Biologic Research will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both a rVaccine candidate and monoclonal antibodies for COVID-19 treatmentIn pre-market trading, the stock was adding 25.19% to $3.23.Qiagen's COVID-19 Test Gets CE Mark In Europe Qiagen NV (NYSE: QGEN) said it has obtained CE marking for its newly-developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic to detect SARS-CoV-2.Pfizer's Eczema Drug Aces Latestage Study Pfizer Inc. (NYSE: PFE) said the Phase 3 JADE COMPARE study that evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 inhibitor, in adults with moderate to severe atopic dermatitis who were also on background topical therapy, met its co-primary efficacy endpoints.View more earnings on IBB"These data, along with other results from other pivotal trials, MONO-1 and MONO-2, will support filings with regulatory bodies, starting with the US Food and Drug Administration (FDA) planned for later this year," the company said.Dicerna's Genetic Disorder Drug Gets Orphan Drug Designation Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) said the FDA granted orphan drug designation to its DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency - a genetic disorder that can cause lung and liver disease.In pre-market trading, the stock was adding 4.09% to $14.Earnings Capricor Therapeutics Inc's (NASDAQ: CAPR) fourth-quarter net loss narrowed from $1.05 per share to 34 cents per share, in line with the consensus. As of Dec. 31, 2019, cash, cash equivalents and marketable securities totaled about $9.9 million, compared to approximately $7.3 million on Dec. 31, 2018.In pre-market trading, the stock was slipping 5.36% to $1.18.Acer Therapeutics Inc (NASDAQ: ACER) said its fourth-quarter loss per share narrowed from 85 cents to 51 cents, while analyst estimated a narrower loss of 48 cents per share. Cash and cash equivalents were $12.1 million as of Dec. 31, 2019, compared to $41.7 million as of Dec. 31, 2018. The company said it believes its cash position will suffice to fund operations till the end of 2020, excluding support for Edsivo development and precommercial activities, and the planned osanetant clinical trial.Separately, the company said the Office of New Drugs of the FDA has denied its appeal of the Complete Response Letter for EDSIVO NDA.In pre-market trading, the stock was slipping 5.94% to $1.90.On The Radar Earnings Vascular Biogenics Ltd (before the market open) Zai Lab Ltd (NASDAQ: ZLAB) (before the market open) Hookipa Pharma Inc (NASDAQ: HOOK) (before the market open) BIOLASE Inc (NASDAQ: BIOL) (before the market open) Auris Medical Holding Ltd (NASDAQ: EARS) (after the close) Curis, Inc. (NASDAQ: CRIS) (after the close) Viveve Medical Inc (NASDAQ: VIVE) (after the close)See more from Benzinga * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Insider Monkey
Hedge Funds Were Buying Novartis AG (NVS) Before Coronavirus Crash
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- Zacks
Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
- Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG.
- Yahoo Finance Video
Trump, White House officials to discuss economic response to coronavirus: Rpt
Reuters is reporting that President Trump will meet with Treasury Secretary Steven Mnuchin and others to discuss potential fiscal policy responses to the coronavirus. Yahoo Finance’s Rick Newman joins Zack Guzman, Brian Cheung and Morning Brew Business Editor and Podcast Host Kinsey Grant on YFi PM.
- GlobeNewswire
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
NEW YORK, March 09, 2020 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
- Yahoo Finance Video
Stocks nosedive as coronavirus cases surpass 100K
Cases of coronavirus surpassed 100,000 worldwide, with New York cases tripling in just 48 hours. Yahoo Finance’s Anjalee Khemlani breaks down the details with Seana Smith.
- Zacks
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
- Yahoo Finance Video
Biopharma companies race to create coronavirus vaccine
As coronavirus cases top 90,000, biopharma companies are racing to create a vaccine. Yahoo Finance’s Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
- American City Business Journals
Dozens of backers chime in on $100M round for hearing loss startup
More than 30 investors handed over money to one of the Boston area’s emerging hearing loss-focused biotechs.
- Reuters
Online voting at AGMs in demand as coronavirus spreads: Swiss tech firm
Online voting at annual shareholder meetings (AGMs) has jumped since the coronavirus outbreak as investors shun large gatherings because of travel restrictions or fear of infection, Swiss tech firm Sherpany said. The company, which counts Swiss giants Novartis, Nestle and Zurich Insurance among its 300 clients worldwide, provides a secure internet platform which lets shareholders vote on motions until the day before AGMs. "We have had a big increase in usage so far, and the AGM season is only just beginning," Sherpany Chief Executive Tobias Haeckermann told Reuters.
- Zacks
Alnylam's Givlaari Gets Approval in Europe for Rare Disease
Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.
- Zacks
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
